Back to top
more

ResMed (RMD)

(Delayed Data from NYSE)

$238.75 USD

238.75
1,334,422

-5.37 (-2.20%)

Updated Oct 1, 2024 04:00 PM ET

After-Market: $238.78 +0.03 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (68 out of 251)

Industry: Medical - Products

Better trading starts here.

Zacks News

ResMed (RMD) Q3 Earnings: Disappointment in the Cards?

ResMed Inc. (RMD) is slated to report third-quarter fiscal 2017 results, after market close on Apr 27.

    ResMed's Study Results for Central Sleep Apnea Hold Promise

    ResMed Inc. (RMD) recently sponsored a study which shows potential treatment of obstructive sleep apnea (OSA) in patients with untreated central sleep apnea (CSA).

      Align Partners Zfx GmbH to Expand iTero Scanner Business

      Align Technology Inc. (ALGN) announced a non-exclusive agreement with digital prosthetic solutions maker, Zfx GmbH on iTero Element intraoral scanners.

        VWR Corp Acquires EPL Archives, Improves Customer Service

        VWR Corporation (VWR) recently acquired the international biorepository services organization, EPL Archives, Inc.

          PetMed Express' New Order Sales Disappoint, Competition Rife

          On Mar 23, we issued an updated research report on Pompano Beach, FL-based PetMed Express, Inc. (PETS).

            Zacks Industry Outlook Highlights: Quidel, OraSure Technologies, ResMed, Inogen and Masimo

            Zacks Industry Outlook Highlights: Quidel, OraSure Technologies, ResMed, Inogen and Masimo

              Walgreen Boots Buyout of Rite Aid Delayed, Other Woes Remain

              On Mar 24, we issued an updated research report on Illinois-based leading pharmacy-led, health and wellbeing enterprise, Walgreens Boots Alliance, Inc. (WBA).

                Medtronic's (MDT) CoreValve Evolut Pro Receives FDA Approval

                Medical device major Medtronic plc (MDT) recently announced that it has received the FDA approval for its CoreValve Evolut PRO valve.

                  Hologic Completes Cynosure Buyout, Boosts Core Business

                  Hologic, Inc. (HOLX) recently announced the completion of it earlier declared acquisition of marketer of aesthetic treatment systems, Cynosure, Inc.

                    Align's iTero Hits 1 Billion Mark, Boosts Scanner Business

                    Align Technology Inc. (ALGN) has recently revealed that more than one million scans have been submitted using its iTero Element scanner in less than two years.

                      Genomic Health's Cancer Test Business Strong, Expenses High

                      On Mar 20, we issued an updated research report on Redwood City, CA-based Genomic Health Inc. (GHDX), a leading global cancer company with a focus on advanced molecular diagnostics.

                        Integer (ITGR) Amends Term B Loan to Lower Interest Rate

                        Integer Holdings Corporation (ITGR) announced that it has completed an amendment to its senior secured credit facilities to lower the interest rate on its Term B Loan Facility.

                          Genomic Health's Breast Recurrence Test Data Encouraging

                          Genomic Health, Inc. (GHDX), a leading molecular diagnostics company, recently presented results from 15 Oncotype DX Breast Recurrence Score studies.

                            Medtronic's Positive 2-Year SURTAVI Data Boosts Corevalve

                            Medtronic plc (MDT) has released the first-ever clinical data from the Surgical Replacement and Transcatheter Aortic Valve Implantation (SURTAVI) Trial.

                              Abbott Laboratories' MitraClip Outcome Positive for DMR

                              Abbott Laboratories (ABT) recently presented one-year positive outcomes from the study of the MitraClip system in transcatheter mitral valve repair (TMVR) procedures in the U.S.

                                Thermo Fisher Poised on Innovation, Global Growth Amid Woes

                                On Mar 17, 2017, we issued an updated research report on Thermo Fisher Scientific Inc. (TMO).

                                  CVS Health Launches Reduced Rx for Affordable Medication

                                  CVS Health Corporation (CVS), a leading name in pharmacy benefit and retail pharmacy, recently announced the launch of a prescription savings program-Reduced Rx.

                                    Medtronic's Melody TPV Wins FDA for Less-Invasive Treatment

                                    Medtronic plc (MDT) recently won FDA approval for Melody Transcatheter Pulmonary Valve for implantation in patients whose surgical bioprosthetic pulmonary heart valves have failed.

                                      Align Technology Hits a 52-Week High on Solid Prospects

                                      Share price of San Jose, CA-based Align Technology, Inc. (ALGN) reached a new 52-week high of $110.87 on Mar 15, eventually closing a bit lower at $110.31.

                                        ResMed (RMD) Up 3.6% Since Earnings Report: Can It Continue?

                                        ResMed (RMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                          ResMed (RMD) Beats Earnings and Revenue Estimates in Q2

                                          ResMed Inc. (RMD) announced second-quarter fiscal 2017 adjusted earnings per share (EPS) of 73 cents, consistent with the prior-year quarter level.

                                            Medical Product Stocks Q4 Earnings Roster: SYK, ISRG, RMD

                                            Medical is one of the broader sectors among the 16 Zacks sectors that is expected to report earnings growth in the fourth quarter.

                                              ResMed (RMD) Q2 Earnings: Disappointment in the Cards?

                                              ResMed Inc. (RMD) is slated to report second-quarter fiscal 2017 results, after market close on Jan 23.

                                                ResMed and Dr. Oz Form SleepScore Labs for Sleep Disorders

                                                ResMed Inc. (RMD) recently formed a joint venture with renowned surgeon and television host Dr. Mehmet Oz and private equity firm Pegasus Capital Advisors, L.P.

                                                  ResMed Achieves Key Milestone in Sleep-Disordered Breathing

                                                  After one billion nights of sleep data was downloaded using ResMed's remote patient monitoring platform AirView, the company reached a landmark in the field of sleep research and treatment of sleep apnea.